Postmenopausal women with HER2 positive breast cancer that also have hormone receptor positive disease can benefit significantly when treatment involves adding Herceptin to the drug Arimidex. Combining these two drugs can lengthen the time women with advanced breast cancer live without their disease progressing.
The full findings were released on Monday at the European Society for Medical Oncology Congress in Istanbul. Roche Pharmaceuticals had announced back in May that Herceptin plus Arimidex combination had produced good results.
"The results are very positive" said Dr. Bella Kaufman of Israel's Chaim Sheba Medical Center who led the research. "In breast cancer, there are not many trials that show double progression-free survival."
